Antimicrobials, and specifically antibiotics, play a crucial role in modern medicine. These precious medicines are not only necessary to treat life-threatening infections, but also underpin most common surgical procedures and many chronic treatments such as chemotherapy and transplant medicine. They also play a crucial role in the health of animals.
The increase in bacterial resistance to antibiotics has been dramatic, and combating this growth is a top priority for global policy and public health. There is a particular concern that antibiotics are losing effectiveness faster than they are being replaced by new, innovative drugs.
This innovation gap is widely acknowledged to be the result of a combination of scientific and commercial barriers. The scientific difficulties are formidable: companies and public funders have invested billions of dollars over the last 20 years, yet no new class of antibiotic for Gram-negative infections has reached approval in over 40 years.
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
